You have no items in your shopping cart.
Capivasertib
Description
Images & Validation
−
Key Properties
−| CAS Number | 1143532-39-1 |
|---|---|
| MW | 428.92 |
| Purity | 97.59% |
| Formula | C21H25ClN6O2 |
| SMILES | NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1 |
| Target | PKA,Akt,mTOR,Autophagy |
Storage & Handling
−| Storage | -20°C |
|---|---|
| Disclaimer | For research use only |

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].
Quick Database Links
Protocol Information
Petros A Tyrakis 1, Domen Kampjut 1, Georgina F Steele 1, H Jonathan G Lindström 1, Deborah Chirnomas 1, Benjamin D Hopkins 2, Marcus D Goncalves 3, Siddhartha Mukherjee 4, Lewis C Cantley 5, Oliver D K Maddocks 6 Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models Br J Cancer ., (2025)
Capivasertib (orb1307109)
Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.
Login to Submit a Review